All PlansPrior AuthHigh impact
Tocilizumab (Actemra®); Tocilizumab-anoh (Avtozma®); Tocilizumab-bavi (Tofidence™); Tocilizumab-aazg (Tyenne®), tocilizumab-aazg, tocilizumab-anoh
BCBS Tennessee·TN · Rheumatology, Oncology, Hematology +2 more·Medical Policy
Effective date
Sep 30, 2026
We identified it
Jul 17, 2026
Summary
This is a NEW medical policy for Tocilizumab (Actemra and biosimilars) that establishes coverage criteria, prior authorization requirements, and documentation standards for multiple FDA-approved and compendial indications including rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and others. The policy is NOT effective until 9/30/2026 and should not be implemented before that date.
Action Required
By September 15, 2026: Billing and clinical teams must prepare for implementation of this new Tocilizumab coverage policy. SPECIFIC ACTIONS: (1) Update prior authorization system to require auth for tocilizumab claims (all formulations: Actemra, Avtozma, Tofidence, Tyenne) with specialty-specific approval criteria; (2) Add documentation requirements to billing checklist—initial requests require treatment history and biomarker results (RF, anti-CCP, CRP/ESR for RA); (3) Configure system to verify prescriber specialty (rheumatologist, oncologist, hematologist, or pulmonologist depending on indication); (4) Train billing staff on 12-month authorization windows for each indication; (5) Build workflow to distinguish between FDA-approved indications (covered if criteria met) and compendial uses (covered if criteria met); (6) Create rejection logic for experimental/investigational uses not listed. CONSEQUENCES: Claims submitted without proper prior authorization or documentation will be denied; claims from non-qualified prescribers will be denied; off-label uses not listed will be denied.